Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.659,26 -800,82 (-2,08%) EUR/USD
1,0712 +0,0011 (+0,11%) Bitcoin EUR
59.821,25 -2.585,67 (-4,14%) CMC Crypto 200
1.387,49 -36,61 (-2,57%)
Vir Biotechnology, Inc. (VIR)
Dopo ore:
| Chiusura precedente | 8,13 |
| Aperto | 8,10 |
| Denaro | 8,00 x 100 |
| Lettera | 8,06 x 200 |
| Min-Max giorno | 8,02 - 8,29 |
| Intervallo di 52 settimane | 7,72 - 27,48 |
| Volume | |
| Media Volume | 1.050.638 |
| Capitalizzazione | 1,092B |
| Beta (5 anni mensile) | 0,41 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,59 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 32,29 |
GlobeNewswireVir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT / 10:00 a.m. ET. A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the
- GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include seven poster presentations, one of which is a late-breaking poster, and on
- GlobeNewswire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on November 2, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section
